FiercePharmaAsia—WuXi’s and Sinobioway’s new sites, Takeda’s financials and R&D plan
admin 18th May 2018 Uncategorised 0China’s WuXi Biologics and Sinobioway are investing hundreds of millions of dollars on biologics facilities; Takeda sees 40% drop in Velcade sales for 2018 and is looking to offload “moderately innovative” assets in its pipeline to cut costs; and more.
More: FiercePharmaAsia—WuXi’s and Sinobioway’s new sites, Takeda’s financials and R&D plan
Source: fierce